REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Jun 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-06-09

Reporting Person: GOLDSTEIN JOSEPH L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-09	Common Stock	M	1000	$273.67	Acquired	14000	Direct
2017-06-09	Common Stock	S	1000	$482.55	Disposed	13000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-09	Non-Qualified Stock Option (right to buy)	$273.67	M	1000	Disposed	2024-01-02	Common Stock (1000)	Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.